テキサスにおける腎臓がんの臨床試験
テキサス内の拠点で、腎臓がんに関する18件の研究が参加者を募集しています。
テキサス内の都市
公式研究テキスト（英語）
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
- Texas Oncology, Dallas
- University of Texas Southwestern Medical Center, Dallas
- University Medical Center & Texas Tech Health Science Center, Lubbock
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06234605Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
- University of Texas - MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05287945Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Research Site, Dallas
- Research Site, Lubbock
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07011719A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07401875Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Texas Oncology - Central South, Austin
- Texas Oncology - Central South, Austin
- Texas Oncology - Central South, Austin
- 他26件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07227415A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- Research Site, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/31更新 · NCT05536141A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
- START San Antonio, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/11更新 · NCT07195682Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
- NEO-811 Dallas Site, Dallas
- NEO-811 Houston Site, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/03更新 · NCT07300241Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- JPS Health Network, Forth Worth
- Baylor Scott and White Biorepository, Temple
被験者募集中観察研究
18歳以上 · 全性別 · 2026/06/29更新 · NCT07327489KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- UT Southwestern Simmons Cancer Center, Dallas
- MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/08更新 · NCT06026410Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/06更新 · NCT06239194A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/13更新 · NCT06362369A Study of VET3-TGI in Patients With Solid Tumors
- Mary Crowley Cancer Research, Dallas
- University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/07更新 · NCT06444815Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
- Houston Methodist Neal Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/12更新 · NCT07050771An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
- University of Texas Southwestern Medical Center, Dallas
被験者募集中健康なボランティア歓迎
18歳以上 · 全性別 · 2026/01/28更新 · NCT04623502cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Elligo Health Research, Inc., Austin
被験者募集中観察研究健康なボランティア歓迎
40歳以上 · 全性別 · 2026/01/20更新 · NCT05366881SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Dallas
- Massive Bio SYNERGY-AI site, Houston
- Massive Bio SYNERGY-AI site, Temple
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
- University of Texas Health Science Center, San Antonio
被験者募集中観察研究健康なボランティア歓迎
全年齢 · 全性別 · 2025/10/15更新 · NCT03160274ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。